Shares of Impax Laboratories Inc. (IPXL) soared 7.5% to $18 in premarket trading on Monday, July 17, after the Hayward, Calif.-based firm secured final approval U.S. Food and Drug Administration approval and an AB therapeutic equivalent rating for a generic version of Concerta (methylphenidate hydrochloride) extended-release tablets USP CII, 18, 27, 36 and 54 mg.

"We are preparing for launch including working to secure API quota and currently expect to launch by the end of this year," said Impax president and CEO Paul Bisaro in a statement.

Among the other biotech movers were Akebia Therapeutics Inc. (AKBA) - Get Report , up nearly 5% to $14.55, and Alder BioPharmaceuticals Inc. (ALDR) - Get Report , up 4.7% to $12.20.

Worried about how to finance your golden years? Register here to watch a free webinar in which TheStreet's Jim Cramer talks with Ken Fisher, founder of Fisher Investments, about the market trends shaping retirement planning today.